Skip to search formSkip to main contentSkip to account menu

MPC-6827

Known as: MPC6827, Microtubule Inhibitor MPC-6827 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

verubulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Erratum to: Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme
2011
2011
Comparison of MPC-6827 activity in xenograft models with different dosing schedules.
e13080 Background: MPC-6827 is a small molecule microtubule disrupting agent that is being evaluated in phase II studies for the… 
2010
2010
Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer
MPC-6827 (Azixa) is a small-molecule microtubule-destabilizing agent that binds to the same (or nearby) sites on β-tubulin as… 
2010
2010
Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma.
8531 Background: MPC-6827 (Azixa) is a microtubule destabilizing agent. This study was designed to establish the safety and… 
2010
2010
A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme.
2095 Background: MPC-6827 (Azixa; 4-arylaminoquinazoline) is a microtubule destabilizing agent that achieves high brain… 
2010
2010
Molecular Medicine in Practice Phase I Clinical Trial of MPC-6827 ( Azixa ) , a Microtubule Destabilizing Agent , in Patients with Advanced Cancer
MPC-6827 (Azixa) is a small-moleculemicrotubule-destabilizing agent that binds to the same (or nearby) sites on b-tubulin as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)